Box 1.

List of questions addressing the impact of randomized trials of CAR T cells in second line for LBCL

FAQ 1	What is the current standard of care for patients with LBCL in second line?
FAQ 2	What are the key results of the three randomized trials of CAR T-cells in second line therapy?
FAQ 3	What are additional results of the three randomized trials of CAR T-cells in second line therapy that should be considered?
FAQ 4	What are the differences between the three studies’ designs and how may that have impacted outcomes?
FAQ 5	If the randomized studies in second line show a difference in PFS/EFS but not in OS, should that change practice?
FAQ 6	Do these trials justify a one size fits all approach in second line treatment of early relapsing aggressive B cell lymphomas?
FAQ 7	If patients get CAR T-cells in second line, what should be the SOC in third line, auto-HCT vs allo-HCT vs other?
FAQ 8	If CAR T cells are the SOC in second line, how will we approach patients referred to the transplant/cell therapy center having already started salvage and having established a CR or PR?
FAQ 9	How should we interpret results from studies in the second line setting when frontline therapies change?
FAQ 10	Since Auto-HCT is currently available in more centers than CAR T cells, will that affect access to care if the SOC changes?
FAQ 11	Is the benefit-cost ratio better for CAR T cells or Auto-HCT in second line therapy of DLBCL? What are potential economic considerations of shifting CAR T to 2nd line?
FAQ 12	Which components should be included in the next series of landmark CAR T-cell trials for frontline?